[Research Report] The epilepsy market size is projected to grow from US$ 7.7 billion in 2022 to US$ 10.7 billion by 2030; it is estimated to record a CAGR of 4.1% during 2022–2030.
Market Insights and Analyst View:
Epilepsy is a chronic disease of the brain that results in disturbed nerve cell activity, causing seizures. It is characterized by recurrent seizures involving either a part of the body or the entire body. Seizures can alter sensations, behaviors, awareness, and muscle movements. Epilepsy may develop as a genetic disorder or through an acquired brain injury, such as a trauma or stroke. The consumer demand for treatments is set to increase due to the heightened vulnerability of elderly patients suffering from epilepsy, who are at a greater risk of the condition.
The factors driving the growth of the epilepsy market include the rising prevalence of epilepsy and growing investments in the development of epilepsy therapies. Moreover, in recent years, there has been a notable increase in the approval of drugs to treat epilepsy, marking a significant step forward in addressing the challenges posed by severe seizures. Growing awareness of the need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs. Further, the development of gene therapy as a promising treatment approach is likely to bring significant epilepsy market trends in the coming years.
Growth Drivers:
Epilepsy, also termed a seizure disorder, is a chronic disease of the brain. The condition may occur due to a genetic disorder or an acquired brain injury, such as a trauma or stroke. It is characterized by recurrent seizures, which are short episodes of involuntary movement of a body part or the entire body. Seizures can modify sensations, behaviors, muscle movements, and awareness. According to data published by the World Health Organization (WHO) in February 2023, epilepsy accounts for a significant share of the worldwide disease burden, affecting nearly 50 million people across the world. Moreover, 4–10 persons per 1,000 individuals are estimated to have active epilepsy (i.e., with the need for treatment or continuing seizures). Nearly 5 million people are diagnosed with epilepsy every year. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. This number can reach as high as 139 per 100,000 individuals in low- and middle-income countries. An upsurge in epilepsy incidence can be attributed to the higher count of road traffic injuries and birth-related injuries and the elevated risk of endemic conditions such as neurocysticercosis or malaria.
The WHO states that approximately 70% of individuals with epilepsy can become seizure-free with the use of medications. Treatments to control epilepsy include anti-epileptic medications, special diets (in addition to anti-seizure medications), and surgery; however, anti-epileptic drug therapy is the primary treatment prescribed for most patients. Thus, the rising prevalence of epilepsy worldwide drives the epilepsy market growth during the forecast period.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Epilepsy Market: Strategic Insights
Market Size Value in US$ 7.7 billion in 2022 Market Size Value by US$ 10.7 billion by 2030 Growth rate CAGR of 4.1% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Epilepsy Market: Strategic Insights
| Market Size Value in | US$ 7.7 billion in 2022 |
| Market Size Value by | US$ 10.7 billion by 2030 |
| Growth rate | CAGR of 4.1% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The epilepsy market analysis has been carried out by considering the following segments: type, route of administration, treatment type, age group, distribution channel, and geography. Based on type, the market is categorized into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In terms of route of administration, the market is classified into oral, parenteral, and others. The market, by treatment type, is segmented into first-generation drugs, second-generation drugs, and third-generation drugs. In terms of age group, the market is bifurcated into adults and children.
Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and others. The geographic scope of the epilepsy market report covers North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Segmental Analysis:
The epilepsy market, by type, is segmented into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In 2022, the generalized epilepsy segment held the largest share of the market. It is expected to register the highest CAGR in the market during 2022–2030. Generalized epilepsy involves widespread electrical disruptions in the brain from the outset. The condition can frequently impact both sides of the body, causing the loss of consciousness. Seizures that arise from both sides of the brain at the same time are characteristic of generalized epilepsy. The goal of therapeutics for generalized epilepsy is to regulate and prevent the brain's excessive electrical activity. These therapeutics may contain medications that target both the cortex and deep brain areas. AEDs are widely adopted for this epilepsy, thereby addressing diverse indications.
Epilepsy Market, by Type – 2022 and 2030
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Based on the route of administration, the epilepsy market is segmented into oral, parenteral, and others. In 2022, the oral segment held the largest share of the market. The market for this segment is expected to grow at the highest CAGR during 2022–2030. Oral administration is a prominent route of AED administration, especially among patients with chronic epilepsy. Oral AEDs primarily include immediate-release and modified-release (delayed-release and extended-release) dosage formulations. Oral medications confer the ease of use, allowing patients to self-administer and adhere to prescribed regimens. This route is favored for its simplicity compared to other administration routes, such as intramuscular and intravenous injections.
Based on treatment type, the epilepsy market is categorized into first-generation drugs, second-generation drugs, and third-generation drugs. The third-generation drugs segment held the largest epilepsy market share in 2022. The segment is estimated to register the highest CAGR during 2022–2030. Third-generation AEDs, identified as advanced or next-generation AEDs, mainly include eslicarbazepine acetate, lacosamide, and cannabidiol. The drugs are claimed to be superior to the first- and second-generation AEDs in terms of safety and efficacy. The majority of new AEDs are used to control focal seizures, as well as in specific epileptic syndromes (Lennox–Gastaut syndrome and Dravet syndrome) and tuberous sclerosis. Most of the third-generation AEDs exhibit fewer adverse effects, resulting in increased patient treatment adherence. These drugs are also effective, safe, and generally well-tolerated in children. Third-generation drugs are gaining importance but are not prescribed as frequently as second-generation anti-epileptic drugs.
Based on age group, the epilepsy market is segmented into adults and children. In 2022, the adult segment held a larger share of the market. It is further expected to register a higher CAGR in the market during 2022–2030. Epilepsy is more likely to develop in adults as some risk factors for this disease are more common in adults; these include diseases affecting brain function (such as Alzheimer’s disease), brain tumors, strokes, and head injuries. According to the Centers for Disease Control and Prevention (CDC), 3 million adults aged 18 or older are living with active epilepsy in the US. Nearly 1 million of these adults are aged 55 or older. As the population ages, even more older people are likely to suffer from epilepsy in the coming years. In 2021, 1.1% of US adults (~2.86 million adults) reported active epilepsy. Thus, medications and treatment strategies often prioritize adult patients, aligning with the demographic prevalence of epilepsy in this age group.
Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest epilepsy market share in 2022. In addition, the retail pharmacies segment is expected to register the highest CAGR in the market during 2022–2030.
Regional Analysis:
The geographic scope of the epilepsy market report encompasses North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant share of the market. The market growth in North America is attributed to a rise in the number of people affected by epilepsy, a growing aging population, ongoing R&D in the field of epilepsy therapeutics, regulatory approvals for new products, and a rise in the number of accidents and brain injuries. In 2022, the US held the largest share of the market in the region.
According to the CDC, nearly 1.2% of individuals in the US have active epilepsy. The condition affects 3 million adults and 470,000 children in the country. The burgeoning number of cases of neurological diseases such as Alzheimer's disease, increasing awareness about neurological disorders, favorable results obtained in research activities, and growing investments in epilepsy drug development are among the main factors driving the overall epilepsy market growth in the US.
In March 2020, Neurelis, Inc. announced the commercial availability of VALTOCO (diazepam nasal spray) to treat stereotypic, intermittent episodes of frequent seizures (i.e., acute repetitive seizures and seizure clusters) that are different from a usual seizure pattern observed in pediatric and adult patients. Similarly, in March 2022, the FDA approved Ztalmy (ganaxolone) to treat seizures related to cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2 and older.
In August 2021, the CDC Epilepsy Program selected the Epilepsy Foundation as its funding recipient under a new cooperative agreement: Improving Systems of Care, Epilepsy Education, and Health Outcomes through National and Community Partnerships. The US$ 17.5 million in federal funds that would be allotted over the next 5 years would support the work of the Epilepsy Foundation and its partners in creating and maintaining a robust public health infrastructure, advancing health equity, improving quality of life, and achieving the best outcomes for all people living with the epilepsies. Therefore, the increasing prevalence of epilepsy, new drug launches, and research and funding initiatives bolster the growth of the epilepsy market in the US.
Industry Developments and Future Opportunities:
Initiatives taken by market players operating in the global epilepsy market are listed below:
- In January 2024, Eisai Co Ltd received approval from the Japanese Ministry of Health, Labour, and Welfare for the sale of Fycompa (perampanel) injection formulations in the country. The product is approved as an alternative therapy when oral administration is temporarily impossible. For instance, the oral administration of the drugs may result in the risk of seizures during surgery. As a result, the company has developed an injection formulation of Fycompa to offer a new form of the drug, alongside the tablet and fine granule formulations that are already available in Japan.
- In May 2023, Neuro3 Therapeutics (Neuro3), which focuses on finding and creating novel medications to treat illnesses of the central nervous system, signed an exclusive global license and option deal with Lundbeck (Denmark). The agreement focuses on KCNQ2 ion channel activators, which have been clinically verified as targets for epilepsy treatment.
Competitive Landscape and Key Companies:
The epilepsy market forecast can help stakeholders plan their growth strategies. Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, Livanova PLC, Novartis AG, Medtronic PLC, GSK PLC, and H. Lundbeck AS are among the prominent players in the market. The market players focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Route of Administration, Treatment Type, Age Group, Distribution Channel, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The global epilepsy market is segmented based on type, route of administration, treatment type, age group, distribution channel. The epilepsy market, by type, is categorized into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In 2022, the generalized epilepsy segment held the largest share of the market. It is expected to register the highest CAGR in the market during 2022–2030.
The epilepsy market was valued at US$ 7.7 billion in 2022.
The epilepsy market is expected to be valued at US$ 10.7 billion in 2030.
The epilepsy market majorly consists of the players, including Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, Livanova PLC, Novartis AG, Medtronic PLC, GSK PLC, and H. Lundbeck AS.
The factors driving the growth of the epilepsy market include the rising prevalence of epilepsy and increasing investments in the development of epilepsy therapies. However, the recall of products hampers the growth of the epilepsy market.
Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epilepsy Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Epilepsy Market – Key Market Dynamics
5.1 Epilepsy Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Epilepsy
5.2.2 Increasing Investments in Development of Epilepsy Therapies
5.3 Market Restraints
5.3.1 Recall of Products
5.4 Market Opportunities
5.4.1 Surge in Awareness Programs Conducted by Organizations
5.5 Future Trends
5.5.1 Gene Therapy as Promising Treatment Approach
5.6 Impact of Drivers and Restraints:
6. Epilepsy Market – Global Market Analysis
6.1 Epilepsy Market Revenue (US$ Million), 2022–2030
7. Epilepsy Market Analysis – by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8. Epilepsy Market Analysis – by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9. Epilepsy Market Analysis – by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
10. Epilepsy Market Analysis – by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11. Epilepsy Market Analysis – by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12. Epilepsy Market – Geographical Analysis
12.1 North America: Epilepsy Market
12.1.1 Overview
12.1.2 North America: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.2.1 North America: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.1.2.2 North America: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.1.2.3 North America: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.1.2.4 North America: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.1.2.5 North America: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.1.3 North America: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.1.3.1 United States: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.1.1 Overview
12.1.3.1.2 United States: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.1.3 United States: Epilepsy Market Breakdown, by Type
12.1.3.1.4 United States: Epilepsy Market Breakdown, by Route of Administration
12.1.3.1.5 United States: Epilepsy Market Breakdown, by Treatment Type
12.1.3.1.6 United States: Epilepsy Market Breakdown, by Age Group
12.1.3.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel
12.1.3.2 Canada: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.2.1 Overview
12.1.3.3 Canada: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.3.1 Canada: Epilepsy Market Breakdown, by Type
12.1.3.3.2 Canada: Epilepsy Market Breakdown, by Route of Administration
12.1.3.3.3 Canada: Epilepsy Market Breakdown, by Treatment Type
12.1.3.3.4 Canada: Epilepsy Market Breakdown, by Age Group
12.1.3.3.5 Canada: Epilepsy Market Breakdown, by Distribution Channel
12.1.3.4 Mexico: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.4.1 Overview
12.1.3.5 Mexico: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.5.1 Mexico: Epilepsy Market Breakdown, by Type
12.1.3.5.2 Mexico: Epilepsy Market Breakdown, by Route of Administration
12.1.3.5.3 Mexico: Epilepsy Market Breakdown, by Treatment Type
12.1.3.5.4 Mexico: Epilepsy Market Breakdown, by Age Group
12.1.3.5.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel
12.2 Europe: Epilepsy Market
12.2.1 Overview
12.2.2 Europe: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.2.1 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.2.2.2 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.2.2.3 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.2.2.4 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.2.2.5 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.2.3 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.2.3.1 United Kingdom: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.1.1 Overview
12.2.3.2 United Kingdom: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
12.2.3.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
12.2.3.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
12.2.3.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
12.2.3.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.3 Germany: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.3.1 Overview
12.2.3.4 Germany: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.4.1 Germany: Epilepsy Market Breakdown, by Type
12.2.3.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
12.2.3.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
12.2.3.4.4 Germany: Epilepsy Market Breakdown, by Age Group
12.2.3.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.5 France: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.5.1 Overview
12.2.3.6 France: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.6.1 France: Epilepsy Market Breakdown, by Type
12.2.3.6.2 France: Epilepsy Market Breakdown, by Route of Administration
12.2.3.6.3 France: Epilepsy Market Breakdown, by Treatment Type
12.2.3.6.4 France: Epilepsy Market Breakdown, by Age Group
12.2.3.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.7 Spain: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.7.1 Overview
12.2.3.8 Spain: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.8.1 Spain: Epilepsy Market Breakdown, by Type
12.2.3.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
12.2.3.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
12.2.3.8.4 Spain: Epilepsy Market Breakdown, by Age Group
12.2.3.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.9 Italy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.9.1 Overview
12.2.3.10 Italy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.10.1 Italy: Epilepsy Market Breakdown, by Type
12.2.3.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
12.2.3.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
12.2.3.10.4 Italy: Epilepsy Market Breakdown, by Age Group
12.2.3.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.11 Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.11.1 Overview
12.2.3.12 Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
12.2.3.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
12.2.3.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
12.2.3.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
12.2.3.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel
12.3 Asia Pacific: Epilepsy Market
12.3.1 Overview
12.3.2 Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.2.1 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.3.2.2 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.3.2.3 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.3.2.4 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.3.2.5 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.3.3 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.3.3.1 China: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.1.1 Overview
12.3.3.2 China: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.2.1 China: Epilepsy Market Breakdown, by Type
12.3.3.2.2 China: Epilepsy Market Breakdown, by Route of Administration
12.3.3.2.3 China: Epilepsy Market Breakdown, by Treatment Type
12.3.3.2.4 China: Epilepsy Market Breakdown, by Age Group
12.3.3.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.3 Japan: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.3.1 Overview
12.3.3.4 Japan: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.4.1 Japan: Epilepsy Market Breakdown, by Type
12.3.3.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
12.3.3.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
12.3.3.4.4 Japan: Epilepsy Market Breakdown, by Age Group
12.3.3.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.5 India: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.5.1 Overview
12.3.3.6 India: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.6.1 India: Epilepsy Market Breakdown, by Type
12.3.3.6.2 India: Epilepsy Market Breakdown, by Route of Administration
12.3.3.6.3 India: Epilepsy Market Breakdown, by Treatment Type
12.3.3.6.4 India: Epilepsy Market Breakdown, by Age Group
12.3.3.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.7 Australia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.7.1 Overview
12.3.3.8 Australia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.8.1 Australia: Epilepsy Market Breakdown, by Type
12.3.3.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
12.3.3.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
12.3.3.8.4 Australia: Epilepsy Market Breakdown, by Age Group
12.3.3.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.9 South Korea: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.9.1 Overview
12.3.3.10 South Korea: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.10.1 South Korea: Epilepsy Market Breakdown, by Type
12.3.3.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
12.3.3.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
12.3.3.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
12.3.3.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.11 Rest of Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.11.1 Overview
12.3.3.12 Rest of APAC: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.12.1 Rest of APAC: Epilepsy Market Breakdown, by Type
12.3.3.12.2 Rest of APAC: Epilepsy Market Breakdown, by Route of Administration
12.3.3.12.3 Rest of APAC: Epilepsy Market Breakdown, by Treatment Type
12.3.3.12.4 Rest of APAC: Epilepsy Market Breakdown, by Age Group
12.3.3.12.5 Rest of APAC: Epilepsy Market Breakdown, by Distribution Channel
12.4 Middle East & Africa Epilepsy Market
12.4.1 Overview
12.4.2 Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.2.1 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.4.2.2 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.4.2.3 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.4.2.4 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.4.2.5 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.4.3 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.4.3.1 Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.1.1 Overview
12.4.3.2 Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.2.1 Saudi Arabia: Epilepsy Market Breakdown, by Type
12.4.3.2.2 Saudi Arabia: Epilepsy Market Breakdown, by Route of Administration
12.4.3.2.3 Saudi Arabia: Epilepsy Market Breakdown, by Treatment Type
12.4.3.2.4 Saudi Arabia: Epilepsy Market Breakdown, by Age Group
12.4.3.2.5 Saudi Arabia: Epilepsy Market Breakdown, by Distribution Channel
12.4.3.3 South Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.3.1 Overview
12.4.3.4 South Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.4.1 South Africa: Epilepsy Market Breakdown, by Type
12.4.3.4.2 South Africa: Epilepsy Market Breakdown, by Route of Administration
12.4.3.4.3 South Africa: Epilepsy Market Breakdown, by Treatment Type
12.4.3.4.4 South Africa: Epilepsy Market Breakdown, by Age Group
12.4.3.4.5 South Africa: Epilepsy Market Breakdown, by Distribution Channel
12.4.3.5 United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.5.1 Overview
12.4.3.6 United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.6.1 United Arab Emirates: Epilepsy Market Breakdown, by Type
12.4.3.6.2 United Arab Emirates: Epilepsy Market Breakdown, by Route of Administration
12.4.3.6.3 United Arab Emirates: Epilepsy Market Breakdown, by Treatment Type
12.4.3.6.4 United Arab Emirates: Epilepsy Market Breakdown, by Age Group
12.4.3.6.5 United Arab Emirates: Epilepsy Market Breakdown, by Distribution Channel
12.4.3.7 Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.7.1 Overview
12.4.3.8 Rest of Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.8.1 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Type
12.4.3.8.2 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Route of Administration
12.4.3.8.3 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Treatment Type
12.4.3.8.4 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Age Group
12.4.3.8.5 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Distribution Channel
12.5 South & Central America: Epilepsy Market
12.5.1 Overview
12.5.2 South and Central America: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.2.1 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.5.2.2 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.5.2.3 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.5.2.4 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.5.2.5 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.5.3 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.5.3.1 Brazil: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.1.1 Overview
12.5.3.2 Brazil: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.2.1 Brazil: Epilepsy Market Breakdown, by Type
12.5.3.2.2 Brazil: Epilepsy Market Breakdown, by Route of Administration
12.5.3.2.3 Brazil: Epilepsy Market Breakdown, by Treatment Type
12.5.3.2.4 Brazil: Epilepsy Market Breakdown, by Age Group
12.5.3.2.5 Brazil: Epilepsy Market Breakdown, by Distribution Channel
12.5.3.3 Argentina: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.3.1 Overview
12.5.3.4 Argentina: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.4.1 Argentina: Epilepsy Market Breakdown, by Type
12.5.3.4.2 Argentina: Epilepsy Market Breakdown, by Route of Administration
12.5.3.4.3 Argentina: Epilepsy Market Breakdown, by Treatment Type
12.5.3.4.4 Argentina: Epilepsy Market Breakdown, by Age Group
12.5.3.4.5 Argentina: Epilepsy Market Breakdown, by Distribution Channel
12.5.3.5 Rest of South & Central America: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.5.1 Overview
12.5.3.6 Rest of South and Central America: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.6.1 Rest of South and Central America: Epilepsy Market Breakdown, by Type
12.5.3.6.2 Rest of South and Central America: Epilepsy Market Breakdown, by Route of Administration
12.5.3.6.3 Rest of South and Central America: Epilepsy Market Breakdown, by Treatment Type
12.5.3.6.4 Rest of South and Central America: Epilepsy Market Breakdown, by Age Group
12.5.3.6.5 Rest of South and Central America: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 CombiGene AB
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 LivaNova Plc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Medtronic Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 GSK Plc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 H. Lundbeck AS
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. Epilepsy Market Segmentation
Table 2. North America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 3. North America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 4. North America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 5. North America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 6. North America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 7. United States: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 8. United States: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 9. United States: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 10. United States: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 11. United States: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 12. Canada: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 13. Canada: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 14. Canada: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 15. Canada: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 16. Canada: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 17. Mexico: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 18. Mexico: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 19. Mexico: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 20. Mexico: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 21. Mexico: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 22. Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 23. Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 24. Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 25. Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 26. Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 27. United Kingdom: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 28. United Kingdom: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 29. United Kingdom: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 30. United Kingdom: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 31. United Kingdom: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 32. Germany: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 33. Germany: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 34. Germany: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 35. Germany: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 36. Germany: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 37. France: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 38. France: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 39. France: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 40. France: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 41. France: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 42. Spain: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 43. Spain: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 44. Spain: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 45. Spain: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 46. Spain: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 47. Italy: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 48. Italy: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 49. Italy: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 50. Italy: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 51. Italy: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 52. Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 53. Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 54. Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 55. Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 56. Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 57. Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 58. Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 59. Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 60. Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 61. Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 62. China: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 63. China: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 64. China: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 65. China: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 66. China: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 67. Japan: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 68. Japan: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 69. Japan: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 70. Japan: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 71. Japan: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 72. India: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 73. India: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 74. India: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 75. India: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 76. India: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 77. Australia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 78. Australia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 79. Australia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 80. Australia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 81. Australia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 82. South Korea: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 83. South Korea: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 84. South Korea: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 85. South Korea: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 86. South Korea: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 87. Rest of APAC: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 88. Rest of APAC: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 89. Rest of APAC: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 90. Rest of APAC: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 91. Rest of APAC: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 92. Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 93. Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 94. Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 95. Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 96. Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 97. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 98. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 99. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 100. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 101. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 102. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 103. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 104. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 105. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 106. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 107. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 108. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 109. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 110. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 111. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 112. Rest of Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 113. Rest of Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 114. Rest of Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 115. Rest of Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 116. Rest of Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 117. South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 118. South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 119. South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 120. South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 121. South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 122. Brazil: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 123. Brazil: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 124. Brazil: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 125. Brazil: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 126. Brazil: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 127. Argentina: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 128. Argentina: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 129. Argentina: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 130. Argentina: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 131. Argentina: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 132. Rest of South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 133. Rest of South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 134. Rest of South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 135. Rest of South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 136. Rest of South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 137. Recent Organic Growth Strategies in Epilepsy Market
Table 138. Recent Inorganic Growth Strategies in the Epilepsy Market
List of Figures
Figure 1. Epilepsy Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2022–2030
Figure 5. Epilepsy Market Revenue, Geography (US$ Mn), 2022 – 2030
Figure 6. Epilepsy Market Share (%) – by Type (2022 and 2030)
Figure 7. Progressive Myoclonic Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Reflex Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Generalized Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Other: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Epilepsy Market Share (%) – by Route of Administration (2022 and 2030)
Figure 12. Oral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Parenteral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Epilepsy Market Share (%) – by Treatment Type (2022 and 2030)
Figure 16. First Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Second Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Third Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Epilepsy Market Share (%) – by Age Group (2022 and 2030)
Figure 20. Adult: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Children: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Epilepsy Market Share (%) – by Distribution Channel (2022 and 2030)
Figure 23. Hospital Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Retail Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. North America: Epilepsy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 27. North America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 28. North America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 29. United States: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 30. Canada: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 31. Mexico: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 32. Europe: Epilepsy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 33. Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 34. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 35. United Kingdom: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 36. Germany: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 37. France: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 38. Spain: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 39. Italy: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 40. Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 41. Asia Pacific: Epilepsy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 42. Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 43. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 44. China: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 45. Japan: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 46. India: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 47. Australia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 48. South Korea: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 49. Rest of APAC: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 50. Middle East & Africa: Epilepsy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 51. Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 52. Middle East and Africa: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 53. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 54. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 55. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 56. Rest of Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 57. South & Central America: Epilepsy Market, By Key Country – Revenue (2022) (US$ Million)
Figure 58. South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 59. South and Central America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 60. Brazil: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 61. Argentina: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 62. Rest of South and Central America: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 63. Growth Strategies in Epilepsy Market
The List of Companies - Epilepsy Market
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- CombiGene AB
- Livanova PLC
- Novartis AG
- Medtronic PLC
- GSK PLC
- H. Lundbeck AS.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Epilepsy Market
Feb 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Feb 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Feb 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Feb 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Feb 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)